Cream to prevent hand-foot syndrome from capecitabine in breast cancer
Part of Cancer, Skin clinical trials.
This trial tests whether a special cream containing N-acetylcysteine and urea can prevent the painful hand-foot syndrome often caused by the chemotherapy drug capecitabine. If you have breast cancer and are about to start capecitabine, this study may help reduce side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have breast cancer that has either been surgically removed with some cancer remaining after chemo (stages I–III) or has spread (stage IV).
- You are scheduled to receive capecitabine chemotherapy (either 2000–2500 mg/m² for 2 weeks on, 1 week off, or a lower daily dose).
- You have never taken a drug that caused hand-foot syndrome (pain, redness, swelling on hands and feet).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study (or within 60 days after).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if electroacupuncture combined with self-administered acupressure can prevent hand-foot syndrome, a common side effect of the chemotherapy drug capecitabine. It is for people with gastrointestinal or breast cancer who are starting capecitabine for the first time.
This trial tests whether a corticosteroid cream can prevent or reduce hand-foot skin reactions caused by liposomal doxorubicin (a type of chemotherapy) in breast cancer patients. If you are starting this chemo and are concerned about skin side effects, this study may offer a way to manage them.
This trial tests if a diclofenac cream can help prevent skin redness, peeling, or pain caused by radiation therapy. It is for people with certain head and neck cancers or breast cancer who are starting radiation treatment.
This study tests a special cream that may prevent skin irritation (radiation dermatitis) caused by radiation therapy for breast cancer. The cream is made from natural weak acids and aims to protect the skin by keeping the skin's microbiome healthy.
This trial tests if adding a new oral targeted therapy (elacestrant) to standard chemotherapy (capecitabine) works better than chemotherapy alone for people with a specific type of advanced breast cancer that is hormone-sensitive (ER-positive) and has stopped responding to hormone therapy.
This trial tests whether using cold therapy (cryotherapy) together with compression can lower the chance of numbness, tingling, or pain in the hands and feet caused by chemotherapy. It may help people planning chemotherapy for breast cancer stay more comfortable and function better.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.